A daily weight-loss pill cut body weight by up to 9.4 percent over 26 weeks in a mid-stage trial, but the result did not climb cleanly with the dose. The group on 120 milligrams lost less weight than the group on 60 milligrams, and the lowest dose did not separate from placebo at all.

The drug is HRS-7535, an oral small molecule from Jiangsu Hengrui Pharmaceuticals that switches on the GLP-1 receptor, the same receptor hit by injectable semaglutide ↗ (Wegovy) and tirzepatide ↗ (Mounjaro and Zepbound). Those weekly shots are peptides, which the gut would digest if swallowed, so they have to be injected. HRS-7535 is a small molecule built to survive the stomach and be taken as a tablet. The Phase 2 results ↗ were published June 22 in Nature Communications.

What the trial did

The study enrolled 235 adults with obesity and no diabetes (body mass index 28 to 40) across 29 centers in China, and split them evenly between once-daily HRS-7535 at 30, 60, 120, or 180 milligrams, or a placebo pill. The question it was built to answer was simple: how much weight do people lose at each dose by week 26.

Average weight loss came in at 3.0 percent on 30 mg, 7.1 percent on 60 mg, 6.2 percent on 120 mg, and 9.4 percent on 180 mg, against 2.5 percent on placebo. Take out the placebo effect and the drug itself added 0.5, 4.6, 3.7, and 6.9 percentage points of loss across the four doses. Only the top three doses beat placebo with statistical confidence (p values of 0.0006, 0.0062, and below 0.0001). The 30 mg dose did not (p = 0.71), which means at that dose the pill was, within the noise, a placebo.

The wobble worth noticing

A clean dose-response curve climbs with every step up in dose. This one did not. The 120 mg group lost less than the 60 mg group, both on the raw number and after the placebo adjustment. The staircase went up, up, back down, then up again.

A non-monotonic result like that can mean a few different things. It can be real biology, a plateau where adding more receptor activation stops adding benefit. It can be the play of chance in arms of roughly 47 people each, small enough that one unusually heavy or light subgroup moves the average. It can reflect who tolerated the climb to a higher dose. The authors do not resolve which, and a 235-person trial is not built to. It is exactly the kind of loose end a larger Phase 3 has to tie off before the 120 mg dose can be trusted or dropped.

Side effects tracked the rest of the class. Gastrointestinal complaints, nausea, vomiting, and diarrhea, were the most common, were mostly mild to moderate, and clustered in the weeks when the dose was being ramped up. That is the familiar GLP-1 tolerability signature, and it is why these drugs are started low and titrated slowly.

Why a pill is the prize

The injectable GLP-1 drugs still win on paper. Semaglutide reaches about 15 percent weight loss over 68 weeks, a longer and deeper run than anything an oral candidate has shown. But a weekly needle is a real barrier, and the next stretch of competition is largely about pills, against Eli Lilly's orforglipron and the oral form of semaglutide. A once-daily tablet that delivers 9 percent in 26 weeks is competitive enough to keep HRS-7535 in that race, as long as the dose-response question gets a clean answer.

The GLP-1 receptor ↗ is the most heavily worked target on peptidemodel, and HRS-7535 is a reminder that the newest entrants are small molecules trying to reproduce, in pill form, what the injectable peptides already do. ↯